Literature DB >> 18571456

The neuropathological basis for depression in Parkinson's disease.

Pasquale G Frisina1, Vahram Haroutunian, Leslie S Libow.   

Abstract

Depression is found in 30-40% of all patients with Parkinson's disease (PD), but its etiology is unclear. Using neuropathology as a signpost for neurotransmitter function, we investigated the prevalence of pathological features found at postmortem and sought to uncover differences between depressed (n=11) and non-depressed (n=9) elderly PD patients. The results indicate a higher prevalence of pathological features in depressed compared to non-depressed PD patients, particularly in catecholamine areas of the brain; the locus coeruleus (neuronal loss: odds ratio=7.2, p=08; gliosis: odds ratio=18.0, p=008); dorsal vagus nerve (gliosis: odds ratio=7.63, p<0.05), and substantia nigra pars compacta (gliosis: odds ratio=2.85, ns). However, neuropathological differences were absent in the dorsal raphe nuclei, amygdala, and cortical regions. Our evidence suggests that depression in PD is related more to catecholaminergic than serotonergic system dysfunction.

Entities:  

Mesh:

Year:  2008        PMID: 18571456      PMCID: PMC3071242          DOI: 10.1016/j.parkreldis.2008.04.038

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  31 in total

Review 1.  Depression in Parkinson's disease: its prevalence, diagnosis, and neurochemical background.

Authors:  M Yamamoto
Journal:  J Neurol       Date:  2001-09       Impact factor: 4.849

2.  SSRIs in the treatment of depression in Parkinson's disease.

Authors:  A F G Leentjens; F W Vreeling; G-J Luijckx; F R J Verhey
Journal:  Int J Geriatr Psychiatry       Date:  2003-06       Impact factor: 3.485

Review 3.  Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages).

Authors:  Heiko Braak; Kelly Del Tredici; Hansjürgen Bratzke; John Hamm-Clement; Daniele Sandmann-Keil; Udo Rüb
Journal:  J Neurol       Date:  2002-10       Impact factor: 4.849

Review 4.  Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease.

Authors:  J R Slaughter; K A Slaughter; D Nichols; S E Holmes; M P Martens
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2001       Impact factor: 2.198

5.  Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions.

Authors:  V Haroutunian; M Serby; D P Purohit; D P Perl; D Marin; M Lantz; R C Mohs; K L Davis
Journal:  Arch Neurol       Date:  2000-08

6.  Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study.

Authors:  M Doder; E A Rabiner; N Turjanski; A J Lees; D J Brooks
Journal:  Neurology       Date:  2003-02-25       Impact factor: 9.910

7.  Depression and Parkinson's disease: a new look at an old problem.

Authors:  Emmeline Edwards; Cheryl Kitt; Eugene Oliver; Judith Finkelstein; Molly Wagster; William M McDonald
Journal:  Depress Anxiety       Date:  2002       Impact factor: 6.505

8.  Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.

Authors:  I Rektorová; I Rektor; M Bares; V Dostál; E Ehler; Z Fanfrdlová; J Fiedler; H Klajblová; P Kulist'ák; P Ressner; J Svátová; K Urbánek; J Velísková
Journal:  Eur J Neurol       Date:  2003-07       Impact factor: 6.089

9.  Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease.

Authors:  Antony J Harding; Emily Stimson; Jasmine M Henderson; Glenda M Halliday
Journal:  Brain       Date:  2002-11       Impact factor: 13.501

10.  Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT.

Authors:  Sang Eun Kim; Joon Young Choi; Yearn Seong Choe; Yong Choi; Won Yong Lee
Journal:  J Nucl Med       Date:  2003-06       Impact factor: 10.057

View more
  37 in total

Review 1.  Somatic treatments for mood disorders.

Authors:  Moacyr A Rosa; Sarah H Lisanby
Journal:  Neuropsychopharmacology       Date:  2011-10-05       Impact factor: 7.853

Review 2.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

3.  Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.

Authors:  N Rampersaud; A Harkavyi; G Giordano; R Lever; J Whitton; Ps Whitton
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

4.  Candidate hippocampal biomarkers of susceptibility and resilience to stress in a rat model of depression.

Authors:  Kim Henningsen; Johan Palmfeldt; Sofie Christiansen; Isabel Baiges; Steffen Bak; Ole Nørregaard Jensen; Niels Gregersen; Ove Wiborg
Journal:  Mol Cell Proteomics       Date:  2012-02-06       Impact factor: 5.911

5.  Subthreshold depression in Parkinson's disease.

Authors:  Daniel A Nation; Heather L Katzen; Spyridon Papapetropoulos; Blake K Scanlon; Bonnie E Levin
Journal:  Int J Geriatr Psychiatry       Date:  2009-09       Impact factor: 3.485

6.  Neuropsychiatric characteristics of GBA-associated Parkinson disease.

Authors:  Matthew Swan; Nancy Doan; Robert A Ortega; Matthew Barrett; William Nichols; Laurie Ozelius; Jeannie Soto-Valencia; Sarah Boschung; Andres Deik; Harini Sarva; Jose Cabassa; Brooke Johannes; Deborah Raymond; Karen Marder; Nir Giladi; Joan Miravite; William Severt; Rivka Sachdev; Vicki Shanker; Susan Bressman; Rachel Saunders-Pullman
Journal:  J Neurol Sci       Date:  2016-08-30       Impact factor: 3.181

7.  Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.

Authors:  Gunasingh J Masilamoni; James W Bogenpohl; David Alagille; Kristen Delevich; Gilles Tamagnan; John R Votaw; Thomas Wichmann; Yoland Smith
Journal:  Brain       Date:  2011-07       Impact factor: 13.501

8.  Affective Correlates of Psychosis in Parkinson's Disease.

Authors:  Stewart A Factor; Michael K Scullin; Alan Freeman; Donald L Bliwise; William M McDonald; Felicia C Goldstein
Journal:  Mov Disord Clin Pract       Date:  2016-06-16

9.  Cholinergic and Dopaminergic Alterations in Nigrostriatal Neurons Are Involved in Environmental Enrichment Motor Protection in a Mouse Model of Parkinson's Disease.

Authors:  Willyan Franco Hilario; Alice Laschuk Herlinger; Lorena Bianchine Areal; Lívia Silveira de Moraes; Tamara Andrea Alarcon Ferreira; Tassiane Emanuelle Servane Andrade; Cristina Martins-Silva; Rita Gomes Wanderley Pires
Journal:  J Mol Neurosci       Date:  2016-09-22       Impact factor: 3.444

Review 10.  Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Petros Skapinakis; Eleni Bakola; Georgia Salanti; Glyn Lewis; Athanasios P Kyritsis; Venetsanos Mavreas
Journal:  BMC Neurol       Date:  2010-06-21       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.